@inbook{654bcb89b7c94ce5ac4572b6e6de8fca,
title = "Pharmacology of mixed NOP/mu ligands",
abstract = "The orvinols, including buprenorphine, emerged from research carried out by Reckitt and Colman in the 1960s and 1970s. Regulatory approval of buprenorphine for the treatment of opioid addiction has been a major success and has ultimately led, in part, to its analgesic activity now being fully exploited. As buprenorphine{\textquoteright}s unique clinical profile is documented, efforts continue to rationalise this activity through understanding of its receptor pharmacology. This has included the development of new orvinols with mixed mu and kappa opioid receptor agonist activity and others with efficacy at mu and NOP receptors, the latter of particular interest for the development of new analgesics. Orvinols with mu and kappa antagonist activity, coupled with NOP receptor partial agonism have also been developed and have potential for the treatment of polydrug abuse.",
author = "L Toll and Khroyan, {T V} and Polgar, {W E} and Husbands, {Stephen M} and Zaveri, {N T}",
year = "2013",
doi = "10.1021/bk-2013-1131.ch017",
language = "English",
isbn = "9780841227828",
series = "ACS Symposium Series",
publisher = "American Chemical Society",
pages = "369--391",
editor = "Mei-Chuan Ko and Husbands, {Stephen M}",
booktitle = "Research and Development of Opioid-Related Ligands",
address = "USA United States",
}